				<section class="content container">
					<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for the acute and maintenance treatment of manic or mixed episodes associated with Bipolar I Disorder as monotherapy in adults.</p>
					<h6>Unique pharmacology sets <a href="#">ABILIFY<sup>&reg;</sup></a> apart</h6>
					<h6 style="margin-top:.2em;font-size:1.3em;"><a href="#">ABILIFY</a> proposed mechanism of action (MOA)*</h6>
					<img src="http://placehold.it/600x400" style="margin-bottom:2em;">
					<div style="width:60%;margin:2em auto;">
						<ul class="content">
							<li>Aripiprazole exhibits high affinity for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2C</sub> and 5-HT<sub>7</sub>, alpha1-adrenergic and histamine H<sub>1</sub> receptors, and moderate affinity for the serotonin reuptake site. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors.</li>
						</ul>
					</div>
					<h6>Proposed mechanism of action (MOA)*</h6>
					<h6 style="margin-top:.2em;font-size:1.3em;">Example of dopamine partial agonist activity<sup>4</sup></h6>
					<img src="http://placehold.it/980x600">
					<div style="width:60%;margin:2em auto;">
						<h5>Pharmacodynamics and pharmacokinetics</h5>
						<ul class="content">
							<li>The efficacy of ABILIFY may be mediated through a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors and antagonist activity at 5-HT<sub>2A</sub> receptors</li>
							<li>The mean elimination half-lives of aripiprazole and dehydro-aripiprazole are 75 hours and 94 hours, respectively</li>
						</ul>
						<p>*The MOA of ABILIFY, as with other drugs having efficacy in MDD and bipolar disorder, is unknown.</p>
					</div>
					<h5>Warning on Suicidality and Antidepressant Drugs</h5>
					<p><strong>Children, adolescents, and young adults taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders are at increased risk of suicidal thinking and behavior. See Full Prescribing Information for complete Boxed WARNING.</strong></p>
				</section>
			
				<?php include '../inc/isi.php'; ?>

				<section class="references container" id="references">
					<p><strong>References:</strong></p>
					<ol class="reference">
						<li>Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. <em>Arch Gen Psychiatry</em>. 2007;64(3):327-337.</li>
						<li>Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. <em>J Psychopharmacol</em>. 2007;21(5):461-471.</li>
						<li>Stahl SM. <em>Essential Psychopharmacology</em>. 2nd ed. Cambridge, United Kingdom: Cambridge University Press; 2000.</li>
					</ol>
				</section>